Get informed when a big investor buys or sells
+ FollowOvervalued by 91.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.30 Billion |
|---|---|
| Enterprise Value | $1.33 Billion |
| Annual dividend | $1.14 |
| Dividend yield | 1.49% |
| Earnings per Share | $4.3 |
| Beta | 0.7 |
| Outstanding Shares | 17,336,000 |
| P/E Ratio | 16.93 |
|---|---|
| PEG | -16.25 |
| Price to Sales | 6.05 |
| Price to Book Ratio | 5.18 |
| Enterprise Value to Revenue | 6.07 |
| Enterprise Value to EBIT | 37.41 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.18 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, t...